Headlines
British pharma industry says drug pricing stance hurts foreign investment
Published by Global Banking and Finance Review
Posted on September 10, 2025
Global Banking and Finance Review
Company
Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by Global Banking and Finance Review
Posted on September 10, 2025
LONDON (Reuters) -Britain's main pharmaceutical lobby group said on Wednesday foreign investment in the sector has fallen due to its approach to drug pricing, as the industry remains locked in dispute over the issue with the UK government.
Drug companies have been in long-running negotiations with British ministers over how much revenue from UK sales firms must return to the country's National Health Service, and the latest talks broke down last month without a resolution.
The dispute continues as U.S. President Donald Trump applies pressure on Britain and the European Union to spend more on drugs from U.S. firms, with the administration still mulling plans for pharmaceutical tariffs.
In a report released on Wednesday into the outlook of the pharmaceutical sector, the Association of the British Pharmaceutical Industry warned of long-term underinvestment in innovative medicines, saying Britain's ranking for FDI in the sector had fallen from second in 2017 to seventh in 2023.
ABPI said that "high clawback rates on pharmaceutical companies' UK revenues exacerbate... persistent structural barriers to investment", and cited several pharma executives who were critical of the government's approach.
"The UK is increasingly being ruled out of consideration as a viable location for pharmaceutical investment," it said.
Trump is due to visit Britain next week on a state visit. While Britain and the U.S. have agreed a deal on some tariffs, the treatment of pharmaceutical firms is yet to be finalised.
The two sides in May agreed to "promptly negotiate significantly preferential treatment outcomes on pharmaceuticals and pharmaceutical ingredients," with Britain saying it would "endeavour to improve the overall environment for pharmaceutical companies".
In July, in a bilateral meeting with Starmer in Scotland, Trump said he could work with Britain on the pharmaceutical sector, and that it wouldn't be used as a block or a "cudgel" in trade talks.
(Reporting by Alistair Smout; Editing by Jan Harvey)